Yesterday (April 29), Lonza, a global partner in the pharmaceutical, biotech, and nutraceutical sectors, announced the introduction of its AI-enabled Route Scouting Service (RSS).
Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).
Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
Yesterday (April 29), Lonza, a global partner in the pharmaceutical, biotech, and nutraceutical sectors, announced the introduction of its AI-enabled Route Scouting Service (RSS).
Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).